Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Commentary|Articles|May 5, 2026
Could Orforglipron Change Obesity Treatment Forever?
Fact checked by: Ron Panarotti
A new oral GLP-1 therapy could reshape obesity treatment by improving access, convenience, and patient uptake compared with injectable options.
Advertisement
Advertisement
In this Q&A with Pharmacy Times, Richard Frank, MD, chief medical officer at Vida, discusses how emerging oral GLP-1 therapies may shift the obesity treatment landscape by offering a more convenient alternative to injectables, potentially improving patient adherence and earlier initiation of care. He highlights key differences in efficacy, tolerability, and real-world use, while emphasizing the importance of individualized treatment selection. Frank also explores how expanded therapeutic options could enhance access and flexibility for patients and providers.
Related to this article
At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
Most patients screened by a hospital pharmacist-led transitions-of-care service had unmet pneumococcal and other vaccine needs, and most accepted vaccination when offered.
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
Advertisement
Advertisement